For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $41.03 in the prior trading day, Hims & Hers Health Inc (NYSE: HIMS) closed at $41.05, up 0.05%. In other words, the price has increased by $0.05 from its previous closing price. On the day, 21.68 million shares were traded. HIMS stock price reached its highest trading level at $42.69 during the session, while it also had its lowest trading level at $40.22.
Ratios:
Our goal is to gain a better understanding of HIMS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 80.50. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.
Needham reiterated its Buy rating for the stock on June 04, 2025, while the target price for the stock was revised from $61 to $65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 10 ’25 when Boughton Soleil bought 2,637 shares for $42.53 per share.
Boughton Soleil sold 2,637 shares of HIMS for $132,114 on Oct 27 ’25. The Chief Legal Officer now owns 158,493 shares after completing the transaction at $50.10 per share. On Oct 27 ’25, another insider, Boughton Soleil, who serves as the Officer of the company, bought 2,637 shares for $50.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 9344970752 and an Enterprise Value of 9833250816. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 75.89, and their Forward P/E ratio for the next fiscal year is 55.22. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.23 while its Price-to-Book (P/B) ratio in mrq is 16.07. Its current Enterprise Value per Revenue stands at 4.448 whereas that against EBITDA is 58.356.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.42, which has changed by 0.53727984 over the last 52 weeks, in comparison to a change of 0.14178503 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $19.15. The 50-Day Moving Average of the stock is -19.89%, while the 200-Day Moving Average is calculated to be -12.26%.
Shares Statistics:
The stock has traded on average 28.25M shares per day over the past 3-months and 29943940 shares per day over the last 10 days, according to various share statistics. A total of 219.12M shares are outstanding, with a floating share count of 204.39M. Insiders hold about 10.22% of the company’s shares, while institutions hold 84.47% stake in the company. Shares short for HIMS as of 1760486400 were 66883420 with a Short Ratio of 2.37, compared to 1757894400 on 66534489. Therefore, it implies a Short% of Shares Outstanding of 66883420 and a Short% of Float of 36.67.
Earnings Estimates
Its stock is currently analyzed by 11.0 different market analysts. The consensus estimate for the next quarter is $0.17, with high estimates of $0.3 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.58 and $0.38 for the fiscal current year, implying an average EPS of $0.48. EPS for the following year is $0.67, with 12.0 analysts recommending between $1.37 and $0.33.
Revenue Estimates
12 analysts predict $617.5M in revenue for. The current quarter. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 12 analysts are estimating revenue of $661.29M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $639.25M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.81B in the next fiscal year. The high estimate is $3.02B and the low estimate is $2.61B.
